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Abstract  Unclassifiable B-cell lymphoma with features intermediate between 
diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is a recently 
recognized category of mature B-cell lymphoma. This represents a heterogeneous 
group of diseases which often pose diagnostic problems in clinical practice, yet its 
distinction from DLBCL and BL is important for its therapeutic and prognostic 
implications. We report the challenging diagnostic process of a 60-year old man. He 
had a CD10 and BCL2-positive, BCL6-negative B-cell malignancy with loss of 
multiple B-cell markers including surface immunoglobulin. The karyotype was 
complex and unusual, including t(2;18)(p12;q21), t(8;14)(q24;q32) and a derivative 
chromosome 22 mimicking a Philadelphia chromosome that led to initial diagnostic 
confusion. A triple-hit gray zone B-cell lymphoma with rearrangements of MYC, 
BCL2, BCL6, both alleles of IGH and likely IGK and IGL was finally diagnosed upon 
additional fluorescence in-situ hybridization (FISH) studies. His disease was 
nonresponsive to intensive combination chemotherapy and he died four months after 
presentation. This case illustrates the diagnostic difficulty encountered in such group 
of B-cell lymphomas and emphasizes the need to integrate morphological, 





B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL is 
a newly introduced category of mature B-cell lymphoma in the 2008 updated WHO 
Classification [1]. It is a heterogeneous group of lymphomas found mostly in elderly 
patients with advanced stage disease [2]. Tumor morphology and/or 
immunophenotype are intermediate between BL and DLBCL. Diagnosis is often 
challenging due to lack of a specific morphologic, immunophenotypic and genetic 
pattern. Prognosis is very poor as they respond neither to BL- or DLBCL-type 
chemotherapeutic regimens [2]. Distinction from BL and DLBCL is therefore very 












The patient was a 60-year old man who complained of fever for three weeks. Physical 
examination detected splenomegaly. There was no hepatomegaly or peripheral 
lymphadenopathy. Screening blood investigations showed mild anemia (hemoglobin 
103 g/L), moderate thrombocytopenia (platelet 74 x109/L), raised liver enzymes 
(alanine aminotransferase 100 U/L, aspartate aminotransferase 186 U/L) and 
markedly elevated lactate dehydrogenase (LDH) (7500 U/L). No abnormal white 
blood cells were seen on peripheral blood smear examination. Computed tomography 
confirmed splenomegaly. In addition, mediastinal lymphadenopathy was observed. 
 Bone marrow aspiration cytology showed many malignant cells that were 
heterogeneous in size, with a high nuclear-to-cytoplasmic ratio, slightly irregular 
nuclei, condensed chromatin, single to multiple small nucleoli and a rim of deep 
basophilic cytoplasm that occasionally contained clear vacuoles (Fig. 1a). The 
cytological finding of condensed chromatin in the malignant cells is more in favor of 
a high grade lymphoma than an acute leukemia. Presence of distinct cytoplasmic 
vacuoles within the intensely basophilic cytoplasm of the malignant cells raised the 
suspicion of a BL. Although the size heterogeneity and nuclear irregularity are 
atypical of BL, findings from gene expression profiling studies have demonstrated 
that lymphomas with a typical expression signature of BL can have a relatively wide 
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morphological spectrum [3,4]. 
 Flow cytometric analysis revealed an abnormal population of B cells expressing 
CD10, CD19, CD79a and HLA-DR. CD38 was strongly expressed but CD20 was 
only weakly positive. Surface and cytoplasmic CD22 and immunoglobulin heavy 
chains and light chains were not detectable (Fig. 2). CD45 expression was strong and 
markers of immaturity including CD34 and terminal deoxynucleotidyl transferase 
(TdT) were not expressed. Lack of expression of multiple B-cell markers suggested a 
diagnosis of common acute lymphoblastic leukemia (cALL). However, the strong 
CD45 expression was unusual in acute leukaemia except for monoblasts. Neither was 
the absence of CD34 and TdT positivity supportive of ALL. Trephine biopsy revealed 
extensive infiltration by medium-sized to occasionally large abnormal lymphoid cells 
with round to irregular nuclei and multiple small nucleoli. A starry sky pattern was not 
evident (Fig 1b). Immunohistochemical staining on showed that the tumor cells were 
weakly positive for CD20. They strongly expressed BCL2 (Fig. 1c) but were negative 
for BCL6. Ki67 staining revealed less than 90% positive cells. Strong BCL2 
expression and a proliferation index less than 95% preclude a diagnosis of BL. A 
germinal center-type DLBCL with loss of multiple B-lineage antigens was thus 
favored.  
 Conventional cytogenetic analysis revealed two related clones partially sharing 
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multiple clonal abnormalities including amplification of 1(q21q32), t(2;18)(p12;q21), 
t(3;22)(q27;q11.2), +7, and t(8;14)(q24;q32) with duplication of the derivative 
chromosome 14 and loss of its normal homologue. Such a complex karyotype was 
highly unusual in BL. The minute derivative chromosome 22 was morphologically 
identical to a Philadelphia chromosome but chromosomes 9 were normal (Fig. 1d). A 
three-way translocation (3;9;22)(q27;q34;q11.2) was suspected but subsequently 
excluded by a metaphase FISH analysis using BCR/ABL1 dual-color dual-fusion 
translocation probes (Abbott Laboratories, Abbott Park, IL) (Fig. 1e). A triple-hit 
B-cell lymphoma was suspected from the breakpoints observed at 3q27, 8q24 and 
18q21, where BCL6, MYC and BCL2 reside, respectively. A metaphase FISH analysis 
using IGH/MYC dual-color dual-fusion translocation probes was performed (Abbott 
Laboratories, Abbott Park, IL), which confirmed IGH-MYC reciprocal translocation 
and duplication of derivative chromosome 14. In addition, an IGH signal was seen on 
the minute derivative chromosome 22 (Fig. 1f). Together with the t(3;22) observed in 
conventional cytogenetic analysis, findings suggested a 3-way translocation 
t(3;8;22)(q27;q24;q11.2)t(8;14). This involved a chromosome 3, a derivative 
chromosome 8 from t(8;14) and a chromosome 22. The second break in the q arm of 
the derivative chromosome 8 occurred distal to the first break, moving the telomeric 
portion of the translocated IGH gene to chromosome 22. Rearrangement of BCL6 in 
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t(3;8;22)(q27;q24;q11.2)t(8;14) (Fig. 1g) and BCL2 in t(2;18)(p12;q21) (data not 
shown) was confirmed by interphase FISH using respective probes (Abbott 
Laboratories, Abbott Park, IL).   
 The modest nuclear pleomorphism and the triple-hit complex karyotype were not 
classical of DLBCL. A diagnosis of B-cell lymphoma unclassifiable with features 
intermediate between DLBCL and BL was deemed most appropriate. The patient was 
given intensive combination chemotherapy Hyper-CVAD (cyclophosphamide, 
vincristine, doxorubicin, dexamethasone) but the response was poor. He died of 













B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL is 
a newly introduced category of mature B-cell lymphoma. Although specific genetic 
markers have not been identified in this group of lymphomas, they often show 
complex cytogenetics with frequent double-hit and occasional triple-hit changes. They 
are thought to strongly overlap with the molecular intermediate lymphomas defined 
by gene expression profiling [5]. The complex karyotype of our case provides many 
diagnostic clues but at the same time it is very challenging to dissect the various 
abnormalities. The exclusion of BCR-ABL1 fusion in this case is of paramount 
importance because its presence indicates a diagnosis of Ph-positive ALL rather than 
a mature B-cell lymphoma. A chemotherapeutic regimen for ALL incorporating a 
tyrosine kinase inhibitor is then necessary [6]. Detection of t(8;14)(q24;q32), which 
suggests IGH-MYC translocation, does not itself exclude a diagnosis of B-cell ALL as 
rare cases of CD10 and TdT-positive precursor B-cell ALL with t(8;14)(q24;q32) have 
been reported [7-9].  
 Loss of immunoglobulin expression in high grade B-cell lymphoma indicated 
either the presence of non-functional somatic hypermutations in multiple 
immunoglobulin genes in lymphoma cells of germinal center origin or multiple 
chromosomal rearrangements disrupting these genes [1]. The absence of detectable 
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immunoglobulin in tumor cells of this case is readily explained by the involvement of 
both IGH genes in the same translocation with MYC, leaving no functional IGH for 
immunoglobulin expression. Translocation breakpoints at 2p12 and 22q11.2 also 
suggest involvement of IGK and IGL, respectively. This is exceptional when 
compared to the usual double-hit lymphomas where typically one IGH is involved in 
rearrangement with MYC and the other IGH with BCL2, or less commonly BCL6. 
Lack of immunoglobulin expression alone in the absence of TdT or CD34 positivity 
should not be used to substantiate a diagnosis of precursor B-cell malignancy, 
especially when karyotyping shows IGH translocation [10].  
  The absence of detectable BCL6 expression in this case is rather unexpected 
[11]. Indeed, a demonstrable BCL6 rearrangement in the t(3;8;22)(q27;q24;q11.2) 
suggests IGL-BCL6 translocation at the breakpoints. The possibility of a missense 
mutation(s) in BCL6 leading to epitope change and immunohistochemical negativity 
cannot be excluded. This phenomenon has been observed in some BCL2-rearranged 
but “BCL2-negative” follicular lymphoma [12].    
 The disease in our patient nicely illustrates the importance of integrating 
morphological, immunophenotypic and genetic information to distinguish this B-cell 
lymphoma, unclassifiable, with features intermediate between DLBCL and BL from 
the classical BL and DLBCL. Guidelines for the differentiation have been provided by 
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Figure 1. (a) Wright-Giemsa stained bone marrow aspirate smear shows a mixture of 




Figure 1. (b) Hematoxylin and eosin stained trephine biopsy shows a dense infiltration 
of lymphoma cells that are mostly medium-sized, with no starry sky appearance, 400x 
original magnification.  
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Figure 1. (c) Immunohistochemical staining for BCL2 shows strong positivity in 
tumor cells, 400x original magnification.  
 15 
 
Figure 1. (d) A karyotype performed from marrow aspirate reveals multiple 
abnormalities, in particular t(2;18)(p12;q21), t(3;22)(q27;q11.2), and t(8;14)(q24;q32) 




Figure 1. (e) Metaphase fluorescence in-situ hybridization (FISH) study using 
dual-color dual-fusion probes for BCR and ABL1 shows no gene fusion. One BCR 
gene (green signal) is translocated en bloc to chromosome 3 in the t(3;22)(q27;q11.2).  
 
Figure 1. (f) Metaphase FISH study employing dual-color dual-fusion IGH (red) and 
MYC (green) probes confirms reciprocal IGH-MYC rearrangement on a derivative 
chromosome 8 and both derivative chromosome 14. An additional IGH signal is seen 
on the derivative chromosome 22 from the observed t(3;22)(q27;q11.2).  
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Figure 1. (g) Interphase FISH study using BCL6 dual-color break apart probes reveals 





                   
Figure 2. Scatter plots from flow cytometric analysis of marrow tumor cells show 
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normal CD19, weak CD20 and no surface and cytoplasmic CD22 expression (upper 
panel, gated on CD45-positive and low side scatter lymphoid population). Surface 
immunoglobulin heavy chains and surface and cytoplasmic light chains are all 
negative (lower panel, gated on CD19-positive cells). 
 
 
